Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety
administered to patients with bloodstream infections and whether telavancin is effective in
treating these infections.
Phase:
Phase 2
Details
Lead Sponsor:
Cumberland Pharmaceuticals Theravance Biopharma Antibiotics, Inc.